Pfizer: Junior Investigator ATTR Amyloidosis Research

Aim: supporting research proposals that advance the understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas:

• Epidemiologic evaluations for ATTR amyloidosis
• Approaches for the early identification and follow-up of ATTR amyloidosis patients
• RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR amyloidosis
• Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)
• Pathophysiology

Funding: up to $75,000.

https://cdn.pfizer.com/pfizercom/2023-01/2023%20RD%20G%20-%20Global%20ATTR%20Amyloidosis%20Research.pdf?BVNX6t3YH3b0jUjJRYDpPvX_noZqu3ld=

https://www.pfizer.com/about/programs-policies/grants/competitive-grants